MOLECULAR EVASION OF ORAL TOLERANCE FOR MCCOSAL VACCINES
MCCOSAL 疫苗口服耐受性的分子规避
基本信息
- 批准号:2071909
- 负责人:
- 金额:$ 14.78万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1994
- 资助国家:美国
- 起止时间:1994-05-01 至 1999-01-31
- 项目状态:已结题
- 来源:
- 关键词:Peyer's patches anergy cytotoxic T lymphocyte diphtheria toxoid enzyme linked immunosorbent assay genetically modified animals helper T lymphocyte immune tolerance /unresponsiveness immunoglobulin A interferons interleukin 4 interleukin 5 interleukin 6 laboratory mouse lymphocyte proliferation mucosal immunity oral administration polymerase chain reaction spleen vaccines
项目摘要
The induction of systemic unresponsiveness to orally administered soluble
proteins and other antigens, termed oral tolerance, has recently taken on
added significance for possible use in clinical applications to prevent
autoimmune disease. However, when we consider oral vaccines for effective
immunity through the Common Mucosal Immune System, the induction of oral
tolerance would not be beneficial since ideal mucosal vaccines should
result in both mucosal and systemic immunity. Thus, one can only
accomplish oral tolerance to self antigens versus immunity to foreign
vaccine proteins when a better understanding of the fundamental mechanisms
of oral tolerance are set forth. The most compelling work to date suggests
that T lymphocytes are the major regulatory cell type responsible for
induction of oral tolerance. However, the precise role of CD4+ versus CD8+
T cells is not yet clear. CD4+ T cells can be divided into two broad
subsets based upon patterns of cytokines produced. Th1 cells secrete IL-2,
IFN-gamma and TNF-beta and induce cell-mediated immunity as well as help
for IgG-subclass responses. In contrast, Th2 cells synthesize IL-4, IL-5,
IL-6 and IL-10 and regulate IgG1, IgA and IgE responses. We have
hypothesized that oral administration of soluble antigens such as
diphtheria toxoid (DT) induces unresponsiveness (including anergy) in the
CD4+ T cell subset. We further hypothesize that oral DT induces anergic
Th1 cells and DT-specific Th2 cells which further suppress the former
subset via production of IL-4 and IL-10. This combined suppression
accounts for DT-specific systemic unresponsiveness. In contrast, DT-
specific Th2-type cells producing IL-5 and IL-6 support IgA anti-DT
responses in mucosal effector sites. To test this hypothesis, the
following specific aims are proposed. l) Examination of DT-specific Th1
and Th2 cell responses in Peyers patches (PP) and spleen (SP) of mice
orally tolerized with DT by using antigen-induced proliferative responses,
as well as cytokine-specific ELISPOT, ELISA and reverse transcription
(RT)-PCR assays. 2) Usage of anti-cytokine-treated i.e., anti-IFN-gamma,
anti-IL-4 or anti-IL-10, as well as IFN-gamma and IL-4 knockout mice to
determine the exact role of in vivo Th1 and Th2 cells in oral tolerance.
3) Involvement of CD8+ T cells for the induction of oral tolerance since
recent work has shown that this subset contains TGF-beta producing cells
which induce bystander suppression. To directly address this issue,
transgenic anti-Lyt-2 or anti-Lyt-3 as well as beta-2 microglobulin (class
I) knockout mice will be used in these studies. 4) Role of intraepithelial
lymphocytes (IELs), especially the gamma/delta TCR+ subset, for
maintenance of mucosal IgA responses in a state of oral tolerance. 5) Test
whether the mucosal adjuvant cholera toxin (CT) can reverse an existing
state of oral tolerance by enhancing DT-specific Th2 cells. The first 3
specific aims are focused on cellular and molecular mechanisms involved in
systemic unresponsiveness, while the last 2 focus more on how the mucosal
IgA response is maintained in the presence of systemic unresponsiveness.
Further, we will examine the mucosal adjuvant CT to determine if systemic
unresponsiveness can be reversed. To accomplish these goals, we will use
the most modern molecular approaches including specific knockout and
transgenic animals which allow in vivo studies of T cell mediated oral
tolerance.
口服可溶性药物诱导全身无反应性
蛋白质和其他抗原,被称为口服耐受,最近表现出
增加了在临床应用中可能使用的重要意义
自身免疫性疾病。然而,当我们考虑口服疫苗是否有效时
免疫通过普通粘膜免疫系统,诱导口服
耐受性不会有好处,因为理想的粘膜疫苗应该
导致粘膜免疫和全身免疫。因此,人们只能
实现口服对自身抗原的耐受与对外来抗原的免疫
当更好地理解疫苗蛋白质的基本机制时
对口服耐受性进行了阐述。迄今为止最引人注目的工作表明
T淋巴细胞是主要的调节细胞类型
诱导口服耐受性。然而,CD4+与CD8+的确切作用
T细胞尚不清楚。CD4+T细胞可分为两大类
基于产生的细胞因子模式的子集。Th1细胞分泌IL-2,
干扰素-γ和肿瘤坏死因子-β诱导细胞免疫以及帮助
用于免疫球蛋白亚类反应。相反,Th2细胞合成IL-4,IL-5,
IL-6和IL-10,并调节IgG1、IgA和IgE反应。我们有
假设口服可溶抗原,如
白喉类毒素(DT)可引起小鼠的无反应(包括无能)
CD4+T细胞亚群。我们进一步假设口服DT可诱导无能
Th1细胞和DT特异性Th2细胞进一步抑制前者
通过产生IL-4和IL-10的亚群。这种联合压制
解释了DT特有的全身性无反应。相比之下,DT-
产生IL-5和IL-6的特异性Th2型细胞支持IgA抗DT
粘膜效应部位的反应。为了检验这一假设,
提出了以下具体目标。L)DT特异性Th1的检测
和Th2细胞在小鼠Peyers斑块(PP)和脾(SP)的反应
通过使用抗原诱导的增殖反应口服DT,
以及细胞因子特异性ELISPOT、ELISAT和逆转录
(RT)-PCR检测。2)使用抗细胞因子治疗,即抗-干扰素-γ,
抗IL-4或抗IL-10,以及干扰素-γ和IL-4基因敲除小鼠
确定体内Th1和Th2细胞在口服耐受中的确切作用。
3)CD8+T细胞参与诱导口服耐受
最近的研究表明,这个亚群含有产生转化生长因子-β的细胞
这会导致旁观者的压制。为了直接解决这个问题,
转基因抗Lyt-2或抗Lyt-3以及β-2微球蛋白(类
I)基因敲除小鼠将用于这些研究。4)上皮内的作用
淋巴细胞(IEL),尤其是伽马/德尔塔TCR+亚群
维持口腔耐受状态下的粘膜免疫球蛋白A反应。5)测试
粘膜佐剂霍乱毒素(CT)能否逆转现有的
通过增强DT特异性Th2细胞的口服耐受状态。前3名
具体的目标集中在细胞和分子机制上。
全身性无反应,而最后两个更关注粘膜如何
免疫球蛋白A反应是在全身无反应的情况下维持的。
此外,我们将检查粘膜佐剂CT以确定全身性
反应迟钝是可以逆转的。为了实现这些目标,我们将使用
最现代的分子方法,包括特定的基因敲除和
允许在体内进行T细胞介导的口腔研究的转基因动物
宽容。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
HIROSHI KIYONO其他文献
HIROSHI KIYONO的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('HIROSHI KIYONO', 18)}}的其他基金
T CELLS/CYTOKINES FOR B CELL RESPONSES IN ORAL DISEASE
T 细胞/细胞因子对口腔疾病中 B 细胞的反应
- 批准号:
6104728 - 财政年份:1998
- 资助金额:
$ 14.78万 - 项目类别:
T CELLS/CYTOKINES FOR B CELL RESPONSES IN ORAL DISEASE
T 细胞/细胞因子对口腔疾病中 B 细胞的反应
- 批准号:
6270278 - 财政年份:1997
- 资助金额:
$ 14.78万 - 项目类别:
T CELLS/CYTOKINES FOR B CELL RESPONSES IN ORAL DISEASE
T 细胞/细胞因子对口腔疾病中 B 细胞的反应
- 批准号:
6238398 - 财政年份:1996
- 资助金额:
$ 14.78万 - 项目类别:
T CELLS/CYTOKINES FOR B CELL RESPONSES IN ORAL DISEASE
T 细胞/细胞因子对口腔疾病中 B 细胞的反应
- 批准号:
6296244 - 财政年份:1996
- 资助金额:
$ 14.78万 - 项目类别:
MOLECULAR EVASION OF ORAL TOLERANCE FOR MUCOSAL VACCINES
粘膜疫苗口服耐受性的分子规避
- 批准号:
2071908 - 财政年份:1994
- 资助金额:
$ 14.78万 - 项目类别:
MOLECULAR EVASION OF ORAL TOLERANCE FOR MCCOSAL VACCINES
MCCOSAL 疫苗口服耐受性的分子规避
- 批准号:
2330414 - 财政年份:1994
- 资助金额:
$ 14.78万 - 项目类别:
MOLECULAR EVASION OF ORAL TOLERANCE FOR MCCOSAL VACCINES
MCCOSAL 疫苗口服耐受性的分子规避
- 批准号:
2071910 - 财政年份:1994
- 资助金额:
$ 14.78万 - 项目类别:
MOLECULAR EVASION OF ORAL TOLERANCE FOR MCCOSAL VACCINES
MCCOSAL 疫苗口服耐受性的分子规避
- 批准号:
2653847 - 财政年份:1994
- 资助金额:
$ 14.78万 - 项目类别:
相似海外基金
The Influence of TCR afinity for self-peptide on the quality and stability of CD8+ cell anergy
TCR对自身肽的亲和力对CD8细胞无反应性质量和稳定性的影响
- 批准号:
473889 - 财政年份:2022
- 资助金额:
$ 14.78万 - 项目类别:
Miscellaneous Programs
Understand mechanisms of mast cell reactivity and induced anergy and how these are modulated by biologics in food allergy treatment
了解肥大细胞反应性和诱导无反应性的机制,以及在食物过敏治疗中生物制剂如何调节这些机制
- 批准号:
2456902 - 财政年份:2020
- 资助金额:
$ 14.78万 - 项目类别:
Studentship
Genetic contribution to loss of B cell anergy during development of type 1 diabetes
1 型糖尿病发展过程中 B 细胞无反应性丧失的遗传因素
- 批准号:
10178141 - 财政年份:2020
- 资助金额:
$ 14.78万 - 项目类别:
Genetic contribution to loss of B cell anergy during development of type 1 diabetes
1 型糖尿病发展过程中 B 细胞无反应性丧失的遗传因素
- 批准号:
10055413 - 财政年份:2020
- 资助金额:
$ 14.78万 - 项目类别:
Genetic contribution to loss of B cell anergy during development of type 1 diabetes
1 型糖尿病发展过程中 B 细胞无反应性丧失的遗传因素
- 批准号:
10431828 - 财政年份:2020
- 资助金额:
$ 14.78万 - 项目类别:
The Role of Cell Surface Receptor Spatial Organization in Maintaining B Cell Anergy
细胞表面受体空间组织在维持 B 细胞无能性中的作用
- 批准号:
553837-2020 - 财政年份:2020
- 资助金额:
$ 14.78万 - 项目类别:
Alexander Graham Bell Canada Graduate Scholarships - Master's
Genetic contribution to loss of B cell anergy during development of type 1 diabetes
1 型糖尿病发展过程中 B 细胞无反应性丧失的遗传因素
- 批准号:
10647749 - 财政年份:2020
- 资助金额:
$ 14.78万 - 项目类别:
The role of Runx1 in the regulation of T cell anergy
Runx1在T细胞无反应性调节中的作用
- 批准号:
10311471 - 财政年份:2020
- 资助金额:
$ 14.78万 - 项目类别:
B cell anergy, modified LDL uptake, and atherosclerosis
B 细胞无反应性、修饰的 LDL 摄取和动脉粥样硬化
- 批准号:
9886286 - 财政年份:2018
- 资助金额:
$ 14.78万 - 项目类别: